Dexa-BEAM is not Effective in Patients with Relapsed or Resistant Aggressive High-Grade Non-Hodgkin's Lymphoma
- 1 January 1999
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 33 (3-4), 305-312
- https://doi.org/10.3109/10428199909058430
Abstract
The aim of the present study was to evaluate the feasibility and response of the Dexa-BEAM regimen as a salvage therapy followed by high-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBCST) in responding patients with high-grade relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL). Sixteen pretreated patients (mean age 44, range 26-59) with relapsed (8) or resistant (8) NHL were treated with 1-4 cycles of Dexa-BEAM (dexamethasone, BCNU, etoposide, cytarabine, melphalan) in order to attain maximal response. Patients achieving complete response (CR) or partial response (PR) received HDCT with PBSCT. The conditioning regimen used was BEAM. Three patients achieved CR and one patient PR, resulting in an overall response rate of 25%. Three of four responding patients underwent high-dose chemotherapy and were successfully transplanted with autologous blood stem cells. Progressive disease developed in one patient after transplantation. Myelosuppression (WHO grade III- grade IV), the major side effect, was observed in all courses of Dexa-BEAM. Myelosuppression-related infection WHO grade IV occurred in four patients. The protocol was not well tolerated in this heavily pretreated group of patients with four severe myelosuppression-related infections WHO grade IV and one treatment-related death. The overall response rate in this study is not comparable to other salvage regimens published and led to the discontinuation of the trial. In conclusion Dexa-BEAM was only effective in a minority of patients with refractory or relapsed aggressive NHL and was not useful as a cytoreductive regimen prior to HDCT.This publication has 17 references indexed in Scilit:
- DIZE (Dexamethasone, Idarubicin, and Continuous Infusion of Ifosfamide and Etoposide): an Effective and Well-Tolerated New Regimen for Patients with Relapsed LymphomaLeukemia & Lymphoma, 1998
- A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's LymphomaLeukemia & Lymphoma, 1997
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993
- Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.Journal of Clinical Oncology, 1992
- Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatinCancer Chemotherapy and Pharmacology, 1992
- Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II studyAnnals of Oncology, 1991
- The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.Journal of Clinical Oncology, 1990
- Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphomaCancer, 1989
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)Blood, 1988
- IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapyBlood, 1982